LABORATORY RESEARCH USE ONLY. NOT INTENDED FOR CONSUMPTION.

CJC-1295 + Ipamorelin — Published Research

Reviewed by: James S.| Last updated: abril 29, 2026|For laboratory reference only

← Back to CJC-1295 + Ipamorelin product page

How to read this CJC-1295 + Ipamorelin research page

This page summarizes published literature for the component pathways commonly reviewed together in catalog contexts: modified GRF/GHRH analog signaling and Ipamorelin ghrelin-receptor signaling. It is structured for literature orientation and documentation review only.

  • Component framing: citations are grouped by receptor-system context rather than by protocol or intended use.
  • Research framing: summaries describe receptor assays and experimental models; they do not establish product claims or therapeutic outcomes.
  • Documentation links: compare the blend listing, COA hub, y research framework.

Panda Peptides products are for research use only. No dosing, administration, reconstitution, treatment, hormone-use, or human-use guidance is provided.

Biblioteca de investigación

Published research on these compounds — for educational purposes only

Dual receptor signaling

This combination has been studied in receptor-signaling models using coordinated peptide agonism. One component activates a class B GPCR pathway through cAMP/PKA signaling, while ipamorelin activates GHS-R1a through phospholipase C/IP3/calcium pathways. Co-stimulation of both receptor systems in pituitary models produced additive signaling output in published rat studies.

Bowers CY et al. “On the activity of a new synthetic hexapeptide in pituitary signaling models.” Endocrinology. 1984. PubMed

Ipamorelin Selectivity Profile

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) is a pentapeptide characterized by selective GHS-R1a activity in pituitary models. In swine pituitary cell culture models, ipamorelin stimulated GH release with an EC₅₀ of approximately 1.3 nM without significant effects on ACTH, cortisol, prolactin, or FSH/LH release at effective concentrations. This selectivity profile distinguishes it from earlier GHS compounds like GHRP-6 and hexarelin, which show broader hormonal stimulation.

Raun K et al. “Ipamorelin, a selective peptide agonist in pituitary models.” Eur J Endocrinol. 1998. PubMed

CJC-1295 (Mod GRF 1-29) Structure and Pharmacokinetics

CJC-1295 without DAC (also known as Modified GRF 1-29) is a tetra-substituted analog of GRF(1-29) with modifications at positions 2 (D-Ala), 8 (Gln), 15 (Ala), and 27 (Leu). These substitutions confer resistance to DPP-IV and other proteolytic enzymes, extending the biological half-life from the approximately 7-minute native peptide half-life to roughly 30 minutes. The peptide retains full agonist activity at the target receptor with equivalent binding affinity to native GRF(1-29).

Ionescu M, Frohman LA. “Pulsatile GH-axis signaling persists during continuous stimulation by CJC-1295, a long-acting GRF analog.” J Clin Endocrinol Metab. 2006. PubMed

Continue reviewing CJC-1295 + Ipamorelin

Use the research references above alongside Panda’s batch documentation and catalog specifications.

Disclaimer: All research citations are provided as references to published laboratory literature only. These materials may summarize in vitro and animal-model findings. Products are sold strictly for laboratory research use only. This page is provided for research-reference and documentation review only.

Reviewed by

James S.

Research content reviewer focused on peptide literature summaries, source quality, and reference clarity.

Editorial Review

Reviewed by Elizabeth D. y James S. — Panda Peptides Research Team.

Last reviewed: May 2026.

This content summarizes published laboratory literature for research-reference purposes only. Products referenced by Panda Peptides are sold strictly for controlled laboratory, analytical, or reference use and are not consumer products.